[秘鲁一家公立医院中幽门螺杆菌根除治疗的治疗依从性及其相关因素]

[Therapeutic adherence to Helicobacter pylori eradication treatment and its associated factors in a public hospital in Peru].

作者信息

Vargas Cárdenas Gloria, Balvin Yanes Lucía, Chaiña Meza Jimena Marisol, Llanos Tejada Félix

机构信息

Servicio de Gastroenterología, Hospital Nacional Arzobispo Loayza. Lima, Perú.

Facultad de Medicina Humana, Universidad de San Martín de Porres. Lima, Perú.

出版信息

Rev Gastroenterol Peru. 2020 Jul-Sep;40(3):224-229.

PMID:33181808

Abstract

OBJECTIVE

To determine the factors associated with adherence to Helicobacter pylori eradication treatment in patients with the infection.

MATERIALS AND METHODS

A longitudinal prospective cohort analytical observational study was conducted, including 100 patients who initiated Helicobacter pylori eradication treatment. The Morisky Green test was applied to measure adherence to treatment and the Battle Test was applied to measure knowledge about Helicobacter pylori infection. The Chi-square test was performed to determine the association of factors with adherence to treatment and logistic regression analysis to estimate crude RR and adjusted RR.

RESULTS

Of the 100 patients, 64% were found to be female. The average age was 49.9 years and 65% were adherent to treatment. Factors associated with lack of treatment adherence were: age under 50 years (adjusted RR 3.95, 95% CI: 1.09-14.33), lack of higher studies (adjusted RR: 5.1, 95% CI: 1.26-20.5) and presence of adverse reactions (adjusted RR: 5.88, 95% CI: 1.56-22.2).

CONCLUSIONS

Most patients were found to be adherent to the treatment. The risk factors for poor adherence were adverse reactions, age under 50 years and lack of higher education.

摘要

目的

确定幽门螺杆菌感染患者坚持根除治疗的相关因素。

材料与方法

开展一项纵向前瞻性队列分析观察性研究，纳入100例开始进行幽门螺杆菌根除治疗的患者。应用莫利斯基-格林测试来衡量治疗依从性，应用巴特尔测试来衡量对幽门螺杆菌感染的知晓情况。进行卡方检验以确定因素与治疗依从性之间的关联，并进行逻辑回归分析以估计粗相对危险度（RR）和调整后的RR。

结果

100例患者中，64%为女性。平均年龄为49.9岁，65%的患者坚持治疗。与治疗依从性差相关的因素有：年龄在50岁以下（调整后的RR为3.95，95%置信区间：1.09 - 14.33）、未接受高等教育（调整后的RR：5.1，95%置信区间：1.26 - 20.5）以及出现不良反应（调整后的RR：5.88，95%置信区间：1.56 - 22.2）。